A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

NCT04497987 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1180

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV2

Interventions

DRUG: Bamlanivimab
DRUG: Placebo
DRUG: Etesevimab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]
[object Object]
[object Object]